To learn more about the New Canaan Urgent Assessment Program, visit its webpage.

Treatment Resistant Schizophrenia in Young Adulthood

Silver Hill Hospital
Treatment resistant schizophrenia refers to the proportion of schizophrenia patients who continue to have symptoms and poor outcomes despite treatment. Rocco Marotta, MD, PhD, Director of the Center for the Treatment and Study of Neuropsychiatric Disorders, and Amanda Fialk, PhD, LCSW, LICSW, Partner and Chief Clinical Officer of The Dorm discussed how this is defined such as failure of different antipsychotics, neuroimaging, and neurobiological characteristics of treatment resistant schizophrenia.

Dr. Marotta and Dr. Fialk reviewed the current treatment strategies available, including medication combinations, and psychotherapies. The presentation concluded by highlighting common barriers to early diagnosis and treatment in young adults.

This event was hosted by The Dorm and Silver Hill Hospital.